Clinical Trials Awards & Advisory Committee (CTAAC) reviews and funds cancer clinical trials. CTAAC is responsible for the review, funding and management of awards for phase I and II studies testing aspects of feasibility or tolerability and/or efficacy, larger phase II and phase III therapeutic clinical trials and sample collections.
CTAAC reviews applications for funding or approval of late phase investigator-led studies. The former Feasibility Study Committee (FSC) was amalgamated into CTAAC in April 2008. CTAAC therefore also funds single or multi-centre prospective therapeutic, diagnostic or prevention phase I and II studies testing aspects of feasibility or tolerability and/or efficacy.
Additionally, CTAAC is now responsible for the review of prospective sample collections from clinical trials that are about to commence or are ongoing. Support will be provided for the collection of tumour blocks and bloods only, unless specific justification can be made by an applicant for the collection of additional sample types.
Applications submitted to CTAAC are assessed based on their scientific and technical merit, taking into consideration comments collected from expert peer reviewers. The Committee meets three times per year.
Further information about the Committee's activities is also available through the Eighth issue of the Clinical and Translational Operations Funding Directorate (CTOF) newsletter, May 2009 (formerly known as the CTAAC and TRICC newsletter).
Other details
To view our terms of reference or our current committee membership, please view the links at the bottom of this page.
List of available schemes
The Clinical Trials Awards and Advisory Committee currently offers the following schemes:
Committee secretariat:
Email: Nicola Keat
Tel: +44 (0) 20 7438 5392
Fax: +44 (0) 20 7438 5450
Committee Members
View members of CTAAC...
Terms of Reference
View the Terms of Reference for CTAAC...
